![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and tolerability of simeprevir (TMC435) 150 mg once daily
with peginterferon and ribavirin for treatment of HCV genotype 1 infection in patients with Metavir score F3 and F4 (PILLAR and ASPIRE trials)
|
|
|
Reported by Jules Levin
AASLD 2012 Nov 10-14 Boston
Fred Poordad,1 Michael W. Fried,2 Stefan Zeuzem,3 Peter Ferenci,4
Oliver Lenz,5 Rekha Sinha,5 Katleen Callewaert,5 Monika Peeters,5
Maria Beumont-Mauviel5
1Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 3J.W. Goethe University Hospital, Frankfurt, Germany; 4Universitätsklinik für Innere Medizin III, Wien, Austria;
5Janssen Infectious Diseases BVBA, Beerse, Belgium
![AASLD1.gif](../images/111412/111412-1/AASLD1.gif)
![AASLD2.gif](../images/111412/111412-1/AASLD2.gif)
![AASLD3.gif](../images/111412/111412-1/AASLD3.gif)
![AASLD4.gif](../images/111412/111412-1/AASLD4.gif)
![AASLD5.gif](../images/111412/111412-1/AASLD5.gif)
![AASLD6.gif](../images/111412/111412-1/AASLD6.gif)
![AASLD7.gif](../images/111412/111412-1/AASLD7.gif)
![AASLD8.gif](../images/111412/111412-1/AASLD8.gif)
![AASLD9.gif](../images/111412/111412-1/AASLD9.gif)
![AASLD10.gif](../images/111412/111412-1/AASLD10.gif)
![AASLD11.gif](../images/111412/111412-1/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|